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Abstract
Hereditary artifacts in BRCA1 gene have a significant contributory role in familial cases of breast
cancer. However, its germline mutational penetrance in sporadic breast cancer cases with respect
to Pakistani population has not yet been very well defined. This study was designed to assess the
contributory role of germline mutations of this gene in sporadic cases of breast cancer. 150 cases
of unilateral breast cancer patients, with no prior family history of breast cancer and no other
disorders or diseases in general with age range 35–75 yrs, were included in this study.
Mutational analysis for hot spots on Exon 2, 3 and 13 of BRCA1 was done by using Single Strand
Conformational Polymorphism (SSCP). Sequence analysis revealed five variants (missense) and one
novel splice site mutation at exon 13. No germline mutation was observed on the remaining exons
with respect sporadic breast cancer cases in Pakistani population. A vast majority of breast cancer
cases are sporadic; the present study may be helpful for designing a better genetic screening tool
for germline BRCA mutations in sporadic breast cancer patients of Pakistani population. Further
studies involving a screening of entire coding region of BRCA1 is required to explore the merits of
genetic diagnosis and counseling in breast cancer patients.
Introduction
Breast cancer is one of the leading causes of death in
women worldwide. BRCA1 (MIM113705) is a high risk-
associated gene responsible for breast cancer of both
hereditary and sporadic origin. Although several studies
around the world and few studies in Pakistan, have
emphasized that germline mutations in BRCA1 are con-
tributory in a significant proportion for the incidence of
breast cancer, the expected ratio in relation to overall prev-
alence of sporadic cancer cases in our local populations
has not been properly clarified.
Nationwide Cancer registry records and epidemiological
surveillance data regarding the various types of cancers are
lacking in Pakistan. However, according to Karachi Cancer
Registry report, the incidence rate of breast cancer is 69.1
Published: 29 August 2008
International Seminars in Surgical Oncology 2008, 5:21 doi:10.1186/1477-7800-5-21
Received: 6 May 2008
Accepted: 29 August 2008
This article is available from: http://www.issoonline.com/content/5/1/21
© 2008 Malik et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Page 1 of 5
(page number not for citation purposes)
International Seminars in Surgical Oncology 2008, 5:21 http://www.issoonline.com/content/5/1/21per 100,000 [1] which is one of the highest in Asian pop-
ulations, excluding Israel. Estimated prevalence of this
gene with respect to familial history is 17% [2].
The estimated ratio of BRCA germline mutations in spo-
radic breast cancer cases is believed to vary significantly in
different local populations of Pakistan, by 4.4 – 11.1%
(Rashid, 2004, Liede, 2002). There were limitations in
these studies. In case of Leide [3] case selection was irre-
spective of the age group, while in Rashid et al [2] sample
selection was mainly confined to familial breast cancer
cases. Moreover both studies were mainly confined to
Punjab province.
The present study was designed in order to determine the
contribution of germline mutations of BRCA1 to sporadic
breast cancer cases from all four provinces of Pakistan. We
have selected hot spots of mutation on BRCA1 gene and
tried to screen exons involved in ring finger domain for-
mation of BRCA1 protein too.
Methods
Breast cancer patients were determined from various hos-
pitals and Nuclear Medicine Institute(s) from January
2006 – March 2007. Peripheral blood samples were col-
lected from Nuclear and Oncology Institutes all over the
country. Ethical approval was obtained from the respec-
tive research committees of these institutes.
Breast cancer cases found suitable, after stringent initial
screening (no family history, age of onset of disease, no
other family prevailing disorders, no earlier sampling
from any other group for any study) were 150 (table 1 and
figure 1). They were classified into four main groups, with
respect to ethnic and geographic origin: as Punjabi,
Pathan, Balochi, and Sindhi. Females free from of haema-
tological disease or malignancy, either in them or their
family history, were involved in the study as controls.
Blood was drawn with informed consent from patients
and these females.
Only female patients were selected for this study, as the
incidence of male breast cancer in our population was
low, and not adequate to justify the penetration. Sporadic
cancer is generally believed to be unilateral but we also
observed 8 cases of bilateral origin in this regard (included
in this study as a single case).
Sample Collection and Storage
Blood samples from each case were collected in blood vac-
cutainer having EDTA as anticoagulant. For storage, trans-
portation and preservation, recommended guidelines
were followed [4]. 100 blood samples from normal indi-
viduals exonerated from any disorder were also collected
with respective origins, so that mutation or polymor-
phism of respective origin could be differentiated.
Isolation and estimation of DNA
Genome isolation was carried out following the recom-
mended protocol [5] with minor modifications of ethanol
precipitation. DNA isolated was first confirmed by agar-
ose gel electrophoreses, then quantified by using spectro-
photometer to use for polymerase chain reaction.
Amplification, Mutation Screening and Sequencing
Primers for exons 2, 3 and 13 were designed from the
sequences available on Genebank (113705). Primer
designing was done with the aid of Primer # 3' software
and intron exon junctions were also included in this study
for a better identification of splice sites variation. The
primer sequences for the respective exons involved in this
study are given in the table 2. After optimization, amplifi-
cation conditions for exons are 95°C for 4 min, 95°C for
30 s, 50°C for 30 s, 72°C for 1 min and 72°C for 45 min.
Graphical display of the number of participants from the four provincesFigure 1
Graphical display of the number of participants from 
the four provinces.
Table 1: Information on source of patients from the participating institutes
Basic Characteristics of cases and Controls Breast Cases (%) Normal Control Group (%)
NFP1: Cases from Punjab Province 66 (44) 25
NFB2: Cases from Blochistan Province 28 (19) 25
NFNWFP3: Cases from North Western Frontier Province 35 (23) 25
NFS4: Cases from Sindh Province 21 (14) 25
Total number 150 100Page 2 of 5
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firm the chances of non-specificity and yield of the ampli-
fied product.
For mutation detection, SSCP technique [6] with few
modifications was used and samples were screened for
any mobility shift in their banding pattern. This change in
mobility shift either predicting any frame shift alterations
or base substitution in the specified region was confirmed
by running normal controls along with the samples. To
check and confirm the findings, sequencing of the respec-
tive sample was done by the aid of Big Dye terminator
Reaction kit available for ABI310. Bioedit software was
use to compare between normal and suspected samples.
Results and discussion
After extensive screening, five samples were found positive
showing an altered mobility shift on the exon 13 of
BRCA1. No mutation was detected with respect to exon 2
and 3 of BRCA1 gene. Sequencing reveals an evidence of
mis-sense variation on 1435 amino acid Ser. of BRCA1
protein. There is novel splice site mutation changing
amino acid 1452 from Ala to Gln and is due to del of A'
reported leading to splice site truncation which has not
been reported in Breast Information Core database as well
(figure 2). The prevalence of the mutations is summarized
in table 3.
The present study was undertaken to evaluate the preva-
lence of germ-line mutations of these genes in sporadic
breast cancer patients on following exons; 2, 3 and 13 of
BRCA1. Reason of choosing these exons included,
1. Out of 1863 amino acids, ring finger domain has been
formed from exons 2 to 5 [7]. Most frequently observed
mutation 185 del AG has altered the cell viability as tested
in ovarian cancers by Nicole et al in 2003 [8].
2. Exon 13 apart from variation study [9] was added with
a intention to seek for target duplication studies later for
those positive variants for geographic relationship as done
by The BRCA1 Exon13 Duplication Screening Group.
Genetic linkage analysis identification [10] and refine
mapping [11,12] provided the evidence of location of
BRCA1 on chromosome 17 of human genome. BRCA1
mutations accounts for 45% in multiple breast cancer
familial cases [13]. BRCA contribution in relation to
familial cases of breast cancer is strongly established. Its
Germline mutation of exon-13 of BRCA1 with splice site deletioFigure 2
Germline mutation of exon-13 of BRCA1 with splice 
site deletion.A: SSCP mobility shift of the amplified region 
in exon-13. White arrow: wild type from normal controls; 
dark arrow: mutated product from a patient showing the 
mobility shift. B: sequence verification of the deleted nucle-
otide as indicated in A. Arrow indicates the missing nucle-
otide A in the exon13 splice site.
Table 2: Primer sequences for exons 2, 3, & 13
BRCA1 EXON PRIMER Sequences(5'-to-3') Product size Tm(°C)
EXON2 F GGTTGTGATTAGTTCTTTGG 458 51.3
R GTGTTGAAAAGGAGAGGAGT 53.4
EXON3 R GAATGAAATGGAGTTGGATT 381 55.81
F AGGATCGTATTCTCTGCTGT 53.98
EXON13 R AGAACCAAGGCTCCATAAT 476 54
F ATTGCATGAATGTGGTTAGA 53.76Page 3 of 5
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monly encountered sporadic forms of breast cancer varies
among different populations [14-17]. This contributory
variation may be attributed to their different gene pool
make and also due to low penetrance genes involvement.
In families with no prior history of breast cancer, fre-
quency of BRCA mutation is found significantly low from
0.02% to 10% [18]. In Asia, the prevalence of BRCA1/2
mutations among unselected breast cancer cases was
reported 5.1% in Philippines [19], and 2.5%–3.1% in
Korea [20-22].
2% of breast cancer cases in largest breast cancer popula-
tion based study in UK population showed association
with BRCA genes with 0.7% attribution of BRCA1
(Anglian Breast Cancer Study Group, 2000) [23]. In the
only population based study of unselected breast cancer
cases, BRCA1 mutations were found in 3/211 American
patients (1.4%). Several hospital based series of unse-
lected breast cancers implicate BRCA1 and BRCA2 in 2–
5% and 0–2% of all cases, respectively [7]. Earlier studies
have estimated the prevalence of deleterious mutations as
5.1 and 6.7% variable by ethnicity [24] in Korean popula-
tion and germline mutations of the BRCA2 gene account
for less than 0.5% of all invasive breast cancers [25]. This
variation may be attributed to difference on genome level
among various ethnic and population heterogeneity. The
reason of marginally low penetrance of BRCA1 gerline
mutations may be attributed to the polygenic involve-
ment and heterogeneity of samples origin too. As in Asia
the overall prevalence of germline mutation varies from
0.8% in Japanese [26] to 8.0% in Signapore region [27]
indicating involvement of other genes and population
response with respect to various types and origin of can-
cers.
Moreover inter individual variation does exist among the
ethnic groups in association with various risk factor as
reported by Peto et al., [28] showing mutation prevalence
as 3.5% before age 35 yr declining to 0.49% in ≥ 50 yrs.
Conclusion
The continuing uncertainty as to the exact penetrance for
breast cancer among BRCA1 mutation carriers may be due
to several factors including differences owing to study
design, allelic heterogeneity and to modifying genetic and
or environmental factors. Pakistani population, although
offers the potential to explore the contribution that con-
sanguinity makes to breast cancer, but that seems to be
specific for hereditary form of the cancer and it might not
be the case for sporadic cancer. It is possible that no or
marginally low germline mutations are present for
BRCA1, specifically in the case of sporadic cancer
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